# Universal Display Corp \\pa\\: Form 10-Q for the period ended Mar 31, 2019

- Company: [Universal Display Corp \\pa\\](/companies/oled.md) (CIK 1005284)
- Form: 10-Q
- Filed: 2019-05-02
- Accepted by EDGAR: May 2, 2019, 16:01 ET
- Period: 2019-03-31
- Accession: 0001564590-19-015318
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1005284/000156459019015318/oled-10q_20190331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1005284/000156459019015318/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $87.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-01-01 to 2019-03-31 | $15.8m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2019-01-01 to 2019-03-31 | $72.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $15.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-01-01 to 2019-03-31 | $12.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | $34.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-01-01 to 2019-03-31 | $6.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | $31.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-01-01 to 2019-03-31 | $0.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-01-01 to 2019-03-31 | 46,931,999 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | $34.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $13.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2019-01-01 to 2019-03-31 | $4.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2019-01-01 to 2019-03-31 | $649.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-03-31 | $225.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $652.2m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $968.2m | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $131.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-03-31 | $252.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-03-31 | $716.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,452 characters.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes above.

### CAUTIONARY STATEMENT

### CONCERNING FORWARD-LOOKING STATEMENTS

This discussion and analysis contains some “forward-looking statements.” Forward-looking statements concern possible or assumed future results of operations, including descriptions of our business strategies and customer relationships. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. These statements are based on assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate in these circumstances.

As you read and consider this discussion and analysis, you should not place undue reliance on any forward-looking statements. You should understand that these statements involve substantial risk and uncertainty and are not guarantees of future performance or results. They depend on many factors that are discussed further in the section entitled (Risk Factors) in our Annual Report on Form 10-K for the year ended December 31, 2018, as supplemented by disclosures, if any, in Item 1A of Part II below. Changes or developments in any of these areas could affect our financial results or results of operations and could cause actual results to differ materially from those contemplated in the forward-looking statements.

All forward-looking statements speak only as of the date of this report or the documents incorporated by reference, as the case may be. We do not undertake any duty to update any of these forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

### OVERVIEW

We are a leader in the research, development and commercialization of organic light emitting diode, or OLED, technologies and materials for use in displays for mobile phones, televisions, tablets, wearables, portable media devices, notebook computers, personal computers and automotive applications, as well as specialty and general lighting products. Since 1994, we have been exclusively engaged, and expect to continue to be primarily engaged, in funding and performing research and development activities relating to OLED technologies and materials, and commercializing these technologies and materials. We derive our revenue primarily from the following:

- sales of OLED materials for evaluation, development and commercial manufacturing;
- intellectual property and technology licensing;
- contract research services in the areas of organic and organometallic materials synthesis research, development and commercialization; and
- technology development and support, including government contract work and support provided to third parties for commercialization of their OLED products.

Material sales relate to our sale of OLED materials for incorporation into our customers’ commercial OLED products or for their OLED development and evaluation activities. Material sales are recognized at the time title passes, which is typically at the time of shipment or at the time of delivery, depending upon the contractual agreement between the parties.

We receive license and royalty payments under certain commercial, development and technology evaluation agreements, some of which are non-refundable advances. These payments may include royalty and license fees made pursuant to license agreements and also license fees included as part of certain commercial supply agreements. These payments are included in the estimate of total contract consideration by customer and recognized as revenue over the contract term based on material units sold at the estimated per unit fee over the life of the contract.

In 2018, the Company entered into a commercial license agreement with Samsung Display Co., Ltd. (SDC). This agreement, which covers the manufacture and sale of specified OLED display materials, was effective as of January 1, 2018 and lasts through the end of 2022 with an additional two-year extension option. Under this agreement, the Company is being paid a license fee, payable in quarterly installments over the agreement term of five years. The agreement conveys to SDC the non-exclusive right to use certain of the Company's intellectual property assets for a limited period of time that is less than the estimated life of the assets.

At the same time the Company entered into the current patent license agreement with SDC, the Company also entered into a supplemental material purchase agreement with SDC. Under the supplemental material purchase agreement, SDC agrees to purchase from the Company a minimum amount of phosphorescent emitter materials for use in the manufacture of licensed products. This minimum commitment is subject to SDC’s requirements for phosphorescent emitter materials and the Company’s ability to meet these requirements over the term of the supplemental agreement.

In 2015, the Company entered into an OLED patent license agreement and an OLED commercial supply agreement with LG Display Co., Ltd. (LG Display), which were effective as of January 1, 2015 and superseded the existing 2007 commercial supply agreement between the parties. The new agreements have a term that is set to expire by the end of 2022. The patent license agreement provides LG Display a non-exclusive, royalty bearing portfolio license to make and sell OLED displays under the Company's patent portfolio. The patent license calls for license fees, prepaid royalties and running royalties on licensed products. The agreements include customary provisions relating to warranties, indemnities, confidentiality, assignability and business terms. The agreements provide for certain other minimum obligations relating to the volume of material sales anticipated over the term of the agreements as well as minimum royalty revenue to be generated under the patent license agreement. The Company generates revenue under these agreements that are predominantly tied to LG Display's sales of OLED licensed products. The OLED commercial supply agreement provides for the sales of materials for use by LG Display, which may include phosphorescent emitters and host materials.

In 2016, the Company entered into long-term, multi-year OLED patent license and material purchase agreements with Tianma Micro-electronics Co. Ltd. (Tianma). Under the license agreement, the Company has granted Tianma non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The license agreement calls for license fees and running royalties on licensed products. Additionally, the Company supplies phosphorescent OLED materials to Tianma for use in its licensed products.

In 2017, the Company entered into long-term, multi-year agreements with BOE Technology Group Co., Ltd. (BOE). Under these agreements, the Company has granted BOE non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The Company also supplies phosphorescent OLED materials to BOE.

In 2018, the Company entered into long-term, multi-year OLED patent license and material purchase agreements with Visionox Technology, Inc. (Visionox). Under the license agreement, the Company has granted Visionox non-exclusive license rights under various patents owned or controlled by the Company to manufacture and sell OLED display products. The license agreement calls for license fees and running royalties on licensed products. Additionally, the Company expects to supply phosphorescent OLED materials to Visionox for use in its licensed products.

In 2016, we acquired Adesis, Inc. (Adesis) with operations in New Castle, Delaware. Adesis is a contract research organization (CRO) that provides support services to the OLED, pharma, biotech, catalysis and other industries. As of March 31, 2019, Adesis employed a team of 89 research scientists, chemists, engineers, and laboratory technicians. Prior to our acquisition in 2016, we utilized more than 50% of Adesis’ technology service and production output. We continue to utilize a significant portion of its technology research capacity for the benefit of our OLED technology development, and Adesis uses the remaining capacity to operate as a CRO in the above-mentioned industries providing contract research services to those third party customers. Contract research services revenue is earned by performing organic and organometallic synthetics research, development and commercialization on a contractual basis for our customers.

We also generate technology development and support revenue earned from government contracts, development and technology evaluation agreements and commercialization assistance fees, which include reimbursements by government entities for all or a portion of the research and development costs we incur in relation to our government contracts. Revenues are recognized as services are performed, proportionally as research and development costs are incurred, or as defined milestones are achieved.

We anticipate fluctuations in our annual and quarterly results of operations due to uncertainty regarding, among other factors:

- the timing, cost and volume of sales of our OLED materials;
- the timing of our receipt of license fees and royalties, as well as fees for future technology development and evaluation;
- the timing and magnitude of expenditures we may incur in connection with our ongoing research and development and patent-related activities; and
- the timing and financial consequences of our formation of new business relationships and alliances.

### RESULTS OF OPERATIONS

### Comparison of the Three Months Ended March 31, 2019 and 2018

|  | Three Months Ended March 31, 2019 | 2018 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| REVENUE | $87,765 | $43,572 | $44,193 |
| COST OF SALES | 15,814 | 7,458 | 8,356 |
| Gross margin | 71,951 | 36,114 | 35,837 |
| OPERATING EXPENSES: |  |  |  |
| Research and development | 15,829 | 12,357 | 3,472 |
| Selling, general and administrative | 11,969 | 10,791 | 1,178 |
| Amortization of acquired technology and other intangible assets | 5,486 | 5,491 | (5) |
| Patent costs | 1,770 | 1,725 | 45 |
| Royalty and license expense | 2,537 | 1,231 | 1,306 |
| Total operating expenses | 37,591 | 31,595 | 5,996 |
| OPERATING INCOME | 34,360 | 4,519 | 29,841 |
| Interest income, net | 2,831 | 1,271 | 1,560 |
| Other income (expense), net | 282 | (47) | 329 |
| Interest and other income, net | 3,113 | 1,224 | 1,889 |
| INCOME BEFORE INCOME TAXES | 37,473 | 5,743 | 31,730 |
| INCOME TAX (EXPENSE) BENEFIT | (5,999) | 216 | (6,215) |
| NET INCOME | $31,474 | $5,959 | $25,515 |

### Revenue

During the three months ended March 31, 2019, we recognized revenue of $87.8 million, an increase of $44.2 million from $43.6 million in the three months ended March 31, 2018. The increase in revenue was due to higher material sales as a result of stronger demand in the OLED display market, as compared to the weakness experienced in the mobile display market segment during the three months ended March 31, 2018.

Revenue derived from OLED sales comprised 97% of total revenue for the three months ended March 31, 2019 as compared to 94% for the three months ended March 31, 2018. The remaining portion of our revenue was derived from contract research services. Contract research services include revenue earned by our subsidiary, Adesis, which performs organic and organometallic synthetics research, development and commercialization on a contractual basis for our customers.

### Cost of sales

Cost of sales for the three months ended March 31, 2019 increased by $8.4 million as compared to the three months ended March 31, 2018 primarily due to an increase in the level of material sales. Included in the cost of sales for the three months ended March 31, 2019 was an excess and obsolete charge of $224,000 due to excess inventory levels in certain products. As a result of the increase in material sales, gross margin for the three months ended March 31, 2019 increased by $35.8 million as compared to the three months ended March 31, 2018 with gross margin as a percentage of sales decreasing to 82% from 83%.

### Research and development

Research and development expenses increased to $15.8 million for the three months ended March 31, 2019, as compared to $12.4 million for the three months ended March 31, 2018. The increase in research and development expenses was primarily due to higher operating costs, including increased contract research activity.

### Selling, general and administrative

Selling, general and administrative expenses increased to $12.0 million for the three months ended March 31, 2019, as compared to $10.8 million for the three months ended March 31, 2018. The increase in selling, general and administrative expenses was primarily due to higher employee-related compensation expenses.

### Amortization of acquired technology and other intangible assets

Amortization of acquired technology and other intangible assets was $5.5 million for both of the three-month periods ended March 31, 2019 and 2018.

### Patent costs

Patent costs increased to $1.8 million for the three months ended March 31, 2019, as compared to $1.7 million for the three months ended March 31, 2018.

### Royalty and license expense

Royalty and license expense increased to $2.5 million for the three months ended March 31, 2019, as compared to $1.2 million for the three months ended March 31, 2018. The increase was due to increased royalties incurred under our amended license agreement with Princeton, USC and Michigan, resulting from an increase in qualifying material sales. See Note 9 to the Consolidated Financial Statements for further discussion.

### Interest and other income (expense), net

Interest income, net was $2.8 million for the three months ended March 31, 2019, as compared to $1.3 million for the three months ended March 31, 2018. The increase in interest income, net was primarily due to the increase in available-for-sale investments held in the current quarter over amounts held in the comparable period in 2018. Other income (expense), net primarily consisted of net exchange gains and losses on foreign currency transactions and rental income. We recorded other income, net of $282,000 for the three months ended March 31, 2019 as compared to other expense, net of $47,000 for the three months ended March 31, 2018.

### Income tax (expense) benefit

We are subject to income taxes in both the United States and foreign jurisdictions. The effective income tax rate was an expense of 16.0% and a benefit of 3.8% for the three months ended March 31, 2019 and 2018, respectively, and we recorded income tax expense of $6.0 million and income tax benefit of $216,000, respectively, for those periods. The recorded amounts include deductions for employee share awards in excess of compensation costs (“windfalls”) under ASU No. 2016-09.

Without the $1.5 million benefit of ASU No. 2016-09, for the three months ended March 31, 2019, the effective income tax rate and income tax expense would have been 20.0% and $7.5 million, respectively, and for the three months ended March 31, 2018, without the $1.3 million benefit of ASU No. 2016-09, the effective income tax rate and income tax expense would have been 19.0% and $1.1 million, respectively.

### Liquidity and Capital Resources

Our principal sources of liquidity are our cash and cash equivalents and our investments. As of March 31, 2019, we had cash and cash equivalents of $225.0 million and short-term investments of $301.6 million, for a total of $526.6 million. This compares to cash and cash equivalents of $211.0 million and short-term investments of $304.3, for a total of $515.3 million, as of December 31, 2018.

Cash provided by operating activities for the three months ended March 31, 2019 was $34.1 million resulting from $31.5 million of net income and $17.8 million due to changes in our operating assets and liabilities, partially offset by a $15.2 million reduction due to non-cash items including amortization of deferred revenue, depreciation and amortization of intangibles. Changes in our operating assets and liabilities related to an increase in deferred revenue of $33.1 million and a reduction of inventory of $1.7 million, partially offset by an increase in accounts receivable of $9.0 million, a reduction of accounts payable, accrued expenses and other liabilities of $5.2 million and an increase in other assets of $2.8 million

Cash provided by operating activities for the three months ended March 31, 2018 was $38.8 million resulting from $6.0 million of net income, $33.9 million due to changes in our operating assets and liabilities, partially offset by a $1.1 million reduction due to non-cash items including amortization of deferred revenue, depreciation and amortization of intangibles. Changes in our operating assets and liabilities related to an increase in deferred revenue of $30.3 million and a decrease in accounts receivable of $29.6 million, partially offset by an increase in inventory of $17.4 million, an increase in other assets of $4.2 million, and a reduction of accounts payable and accrued expenses of $4.4 million.

Cash used in investing activities was $9.1 million for the three months ended March 31, 2019, as compared to cash provided by investing activities of $14.5 million for the three months ended March 31, 2018. The increase in cash used by investing activities of $23.5 million was primarily due to the timing of maturities and purchases of investments resulting in net sales of $4.6 million for the three months ended March 31, 2019, as compared to net sales of $23.2 million for the three months ended March 31, 2018, and an increase in purchases of intangibles and property, plant and equipment of $5.0 million for the three months ended March 31, 2019 compared to the three months ended March 31, 2018. The increase in property, plant and equipment purchases during 2019 was primarily due to the purchase of additional property in Ewing, New Jersey as part of our plan to expand operations.

Cash used in financing activities was $10.9 million for the three months ended March 31, 2019, as compared to $8.9 million for the three months ended March 31, 2018. The increase in cash used in financing activities of $2.0 million was due to an increase in the cash payment of dividends in the current year of $1.9 million and an increase in the repurchase of common stock of $172,000, partially offset by a decrease in the payment of withholding taxes related to stock-based compensation to employees of $75,000 and an increase in proceeds from the issuance of common stock of $3,000.

Working capital was $520.6 million as of March 31, 2019, compared to $501.7 million as of December 31, 2018. The increase in working capital was primarily due to an increase in cash and cash equivalents and accounts receivable and a decrease in accrued expenses, partially offset by an increase in deferred revenue and other current liabilities.

We anticipate, based on our internal forecasts and assumptions relating to our operations (including, among others, assumptions regarding our working capital requirements, the progress of our research and development efforts, the availability of sources of funding for our research and development work, and the timing and costs associated with the preparation, filing, prosecution, maintenance, defense and enforcement of our patents and patent applications), that we have sufficient cash, cash equivalents and short-term investments to meet our obligations for at least the next twelve months.

We believe that potential additional financing sources for us include long-term and short-term borrowings, public and private sales of our equity and debt securities and the receipt of cash upon the exercise of outstanding stock options. It should be noted, however, that additional funding may be required in the future for research, development and commercialization of our OLED technologies and materials, to obtain, maintain and enforce patents respecting these technologies and materials, and for working capital and other purposes, the timing and amount of which are difficult to ascertain. There can be no assurance that additional funds will be available to us when needed, on commercially reasonable terms or at all, particularly in the current economic environment.

### Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect our reported assets and liabilities, revenues and expenses, and other financial information. Actual results may differ significantly from our estimates under other assumptions and conditions.

We believe that our accounting policies related to revenue recognition and deferred revenue, inventories, and income taxes are our “critical accounting policies” as contemplated by the SEC.

Refer to our Annual Report on Form 10-K for the year ended December 31, 2018, for additional discussion of our critical accounting policies.

### Contractual Obligations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2018 for a discussion of our contractual obligations.

### Off-Balance Sheet Arrangements

As of March 31, 2019, we had no off-balance sheet arrangements in the nature of guarantee contracts, retained or contingent interests in assets transferred to unconsolidated entities (or similar arrangements serving as credit, liquidity or market risk support to unconsolidated entities for any such assets), or obligations (including contingent obligations) arising out of variable interests in unconsolidated entities providing financing, liquidity, market risk or credit risk support to us, or that engage in leasing, hedging or research and development services with us.

## Market risk

As filed, 1,021 characters.

We do not utilize financial instruments for trading purposes and hold no derivative financial instruments, other financial instruments or derivative commodity instruments that could expose us to significant market risk other than our investments disclosed in “Fair Value Measurements” in Note 4 to the Consolidated Financial Statements included herein. We generally invest in investment grade financial instruments to reduce our exposure related to investments. Our primary market risk exposure with regard to such financial instruments is to changes in interest rates, which would impact interest income earned on investments. However, based upon the conservative nature of our investment portfolio and current experience, we do not believe a decrease in investment yields would have a material negative effect on our interest income.

Substantially all our revenue is derived from outside of North America. All revenue is primarily denominated in U.S. dollars and therefore we bear no significant foreign exchange risk.

## Controls and procedures

As filed, 1,520 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2019. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of the end of the period covered by this report, are effective to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. However, a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 182 characters.

There have been no material changes to the risk factors previously discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018.

Filed May 2, 2019.
Source: SEC EDGAR, the filing index for accession 0001564590-19-015318. Last ingested by Listed: Nov 5, 2026, 15:33 ET. No prices; not investment advice.